Pharmacokinetics and pharmacodynamics of alirocumab in patients with autosomal dominant hypercholesterolemia associated with PCSK9 gain-of-function or ApoB loss-of-function mutations
25 August 2018 (13:57 - 14:06)
Organised by:
Abstract
About the speaker
Nantes (France)
8 More presentations in this session
Professor N. Vorobyeva (Moscow, RU)
Access the full session
The Event
ESC Congress 2018
25 August 2018
13:57 CET
